Neuroblastoma Research and Treatments

Single-cell and Spatial Omics Reveals Region-Specific Plasticity and Therapeutic Vulnerabilities in Metastatic High-Risk Neuroblastoma

This study uses single-cell and spatial omics to identify plasticity and therapeutic targets in metastatic high-risk neuroblastoma.

5-hydroxymethylcytosine deposition mediates Polycomb Repressive Complex 2 function in MYCN-amplified neuroblastoma

This study shows that 5-hydroxymethylcytosine (5-hmC) and H3K27me3 co-localize on PRC2 target genes in MYCN-amplified neuroblastoma, repressing developmental genes and sensitizing tumors to DNA demethylating agents.

Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma

This paper develops a mutation-independent liquid biopsy method using DNA methylation to monitor high-risk neuroblastoma through blood plasma-derived cfDNA.

Comparative ASCL1 interactome analysis reveals CDK2-Cyclin A2 as suppressors of differentiation in MYCN-amplified neuroblastoma

The paper compares ASCL1 interactomes in neuroblastoma cell lines to identify CDK2-Cyclin A2 as suppressors of differentiation in MYCN-amplified cells.

MYCN inhibits TrkC-mediated differentiation in neuroblastoma cells via disruption of the PKA signalling pathway

This study shows MYCN inhibits TrkC-induced differentiation in neuroblastoma by disrupting PKA signaling, with implications for targeting PKA to treat high-risk cases.

RUVBL1 and RUVBL2 are druggable MYCN regulators in neuroblastoma.

This study identifies RUVBL1 and RUVBL2 as druggable regulators of MYCN in neuroblastoma, showing their inhibition reduces MYC signaling and induces cell cycle arrest and apoptosis.

Targeting replication stress in neuroblastoma by exploiting the synergistic potential of second generation RRM2 and CHK1 inhibitors

This study identifies synergistic effects of second-generation RRM2 and CHK1 inhibitors in neuroblastoma and sarcomas, showing enhanced replication stress and apoptosis.

Rho GTPases signaling mediates aggressiveness and differentiation in neuroblastoma tumors

This study investigates Rho GTPase signaling in neuroblastoma, finding dysregulation associated with aggressiveness and identifying Cdc42 as a key regulator of differentiation and stemness.

Repurposing statins and phenothiazines to treat chemoresistant neuroblastoma.

This study repurposes statins and phenothiazines to treat chemoresistant neuroblastoma, showing synergistic effects and improved survival in preclinical models.

Differential chromatin response to retinoic acid in neuroblastoma according to type of ATRX mutation

This study shows that ATRX mutation type affects chromatin response to retinoic acid in neuroblastoma, influencing differentiation and therapeutic response.

Inclusion of JNK-independent drugs within multi-agent chemotherapy improves response in relapsed high-risk neuroblastoma

The paper identifies JNK-independent drugs that, when combined with standard chemotherapy, improve response in relapsed high-risk neuroblastoma by exploiting differential apoptotic network utilization.

OXPHOS TARGETING OF MYCN-AMPLIFIED NEUROBLASTOMA

This study identifies a synergistic combination of DPI and MitoQ that targets mitochondrial metabolism in MYCN-amplified neuroblastoma cells, enhancing chemotherapeutic efficacy.

HIF2α negatively regulates MYCN protein levels and promotes a low-risk noradrenergic phenotype in neuroblastoma.

This paper shows that HIF2α reduces MYCN protein levels and promotes a low-risk noradrenergic phenotype in neuroblastoma, suggesting HIF2 has tumor suppressor rather than oncogenic function.

γδ T cells are the prime anti-tumoral T cells in pediatric neuroblastoma

The paper shows that γδ T cells, not β T cells, are the main anti-tumoral immune cells in pediatric neuroblastoma after chemotherapy.

Spatial transcriptomics exploration of the primary neuroblastoma microenvironment unveils novel paracrine interactions

The paper uses spatial transcriptomics to analyze neuroblastoma microenvironments, identifying novel paracrine interactions between cancer cells and surrounding cells.

Novel miRNA-inducing drugs enable differentiation of retinoic acid-resistant neuroblastoma cells

The paper identifies PP121 and bufalin as drugs that induce differentiation in retinoic acid-resistant neuroblastoma cells through miR-124 activation, maintaining differentiated states for over 16 weeks.

Bone morphogenetic protein (BMP) signaling determines neuroblastoma cell fate and sensitivity to retinoic acid.

The paper investigates RA's limited effect on primary neuroblastoma tumors but efficacy in clearing bone marrow cells, identifying BMP signaling as a key determinant of cell fate and RA sensitivity.

Lineage-dependence of the neuroblastoma surfaceome defines tumor cell state-dependent and independent immunotherapeutic targets

This paper identifies cell state-dependent and -independent immunotherapeutic targets in neuroblastoma by analyzing subtype-specific gene expression and validating targets through experimental methods.

Epac activation reduces trans-endothelial migration of undifferentiated neuroblastoma cells and cellular differentiation with a CDK inhibitor further enhances Epac effect.

Copy-number dosage regulates telomere maintenance and disease-associated pathways in neuroblastoma

The paper identifies gene dosage effects on telomere maintenance and disease pathways in neuroblastoma using genomic and transcriptomic data from 115 tumors.

DKK1, a negative regulator of Wnt signaling, is a novel inducer of neuroblastoma differentiation

This study shows DKK1 inhibits neurosphere formation and promotes neuronal differentiation in SHSY5Y cells, with synergistic effects when combined with retinoic acid.

5-hydroxymethylcytosine profiling of cell-free DNA identifies bivalent genes that are prognostic of survival in high-risk neuroblastoma.

The paper identifies bivalent genes in neuroblastoma cell-free DNA associated with poor prognosis in high-risk patients.

Adrenergic and mesenchymal signatures are identifiable in cell-free DNA and correlate with metastatic disease burden in children with neuroblastoma

The paper identifies adrenergic and mesenchymal signatures in cell-free DNA 5-hmC profiles and shows their correlation with metastatic burden in neuroblastoma patients.

BARD1 germline variants induce haploinsufficiency and DNA repair defects in neuroblastoma

This study identifies BARD1 germline variants associated with reduced BARD1 expression and DNA repair defects in neuroblastoma, showing haploinsufficiency and increased genomic instability.

Clonal evolution during metastatic spread in high-risk neuroblastoma

This study traces clonal evolution in high-risk neuroblastoma using genomic data from 470 samples, showing metastatic clones can remain dormant and later cause relapses.

Somatic structural variation targets neurodevelopmental genes and identifies SHANK2 as a tumor suppressor in neuroblastoma

This study identifies somatic structural variations in neuroblastoma, showing their enrichment in neurodevelopmental genes and the tumor suppressor role of SHANK2.

Epigenomic profiling of neuroblastoma cell lines

The paper provides ChIP-Seq and ATAC-Seq data for MYCN, MYC, and histone marks in neuroblastoma cell lines to study gene regulation and enhancer dynamics.

A deep neural network approach to predicting clinical outcomes of neuroblastoma patients

This paper develops a deep neural network approach for predicting neuroblastoma patient outcomes using graph-based feature extraction, achieving higher accuracy than traditional models.

IRE1α is critical for kaempferol induced neuroblastoma differentiation

This study shows kaempferol induces neuroblastoma differentiation via the IRE1-XBP1 pathway by activating IRE1's endoribonuclease activity.